Detail akcie Regeneron Pharm online

Business Summary: Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Regeneron Pharmaceuticals Inc revenues decreased 1% to $3.15B. Net income decreased 12% to $722M. Revenues reflect EYLEA segment decrease of 16% to $1.2B, Roche segment decrease of 100% to $500K. Net income also reflects Research and development increase of 26% to $706.5M (expense), selling increase of 15% to $602.8M (expense).